Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
52wk Rangeundefined - undefined
Day's RangeN/A - N/A
Avg Vol (3m)N/A
  • American City Business Journals5 months ago

    Meet FDA critic Joseph Gulfo, the Antonin Scalia of the life sciences

    If scientists still can’t determine whether coffee, red wine and aspirin are ultimately good for us, how can the U.S. Food and Drug Administration say whether any of the drugs it reviews will help patients in the long run? Gulfo, the former CEO of MELA Sciences, argues the FDA too often interprets the meaning of “effective” as beneficial for the average patient over the long run, as opposed to simply doing what the drugmaker claims. There’s a long list of drugs that have been rejected — despite patient objections — because the FDA said they didn’t prove effectiveness.

  • MELA Sciences, Inc. Earnings Q3, 2015
    Capital Cube8 months ago

    MELA Sciences, Inc. Earnings Q3, 2015

    Click here to see latest analysisMELA Sciences, Inc. reports financial results for the quarter ended September 30, 2015.We analyze the earnings along side the following peers of MELA Sciences, Inc. – Accuray Incorporated, Perseon Corporation, Bovie Medical Corporation, Varian Medical Systems, Inc., Danaher Corporation, PhotoMedex, Inc., General Electric Company, IsoRay, Inc. and iCAD, Inc. (ARAY-US, […] (Read more...) The post MELA Sciences, Inc. Earnings Q3, 2015 appeared first on CapitalCube.